Mindblown: a blog about philosophy.
-
Apple Beats Earnings, but 3 Risks Weigh on AAPL Stock
The move in Apple stock after earnings presents a distinction between owning a strong business and buying its shares at an attractive price.
-
Wall Street Sees More Upside for PLTR Stock After Q3 Earnings Selloff
Despite strong earnings, PLTR stock fell as investors focused on slower contract value growth and relatively flat remaining performance obligations.
-
Analysts Still Love AAPL Stock Despite Tepid Q4 Earnings
The bullish case for AAPL stock rests on Apple’s ability to keep customers engaged and give them reasons to upgrade or purchase additional services.
-
Palantir’s Commercial Revenue Breakthrough Raises the Stakes for PLTR
Palantir’s U.S. commercial business is now larger than its government business, but can it turn those contracts into sales without sacrificing its margins.
-
Candy Stocks: Why Mondelez Has the Winning Edge Over Hershey
On paper, Mondelez and Hershey had similar quarters. Here’s how they stack up after earnings, and what each candy stock offers investors right now.
-
Marvell Makes a $115 Billion Bet on Moving AI Data Faster
Bigger AI systems need faster connections. Marvell believes buying Lumentum will help it meet that demand and win more business.
-
Crocs Is Rebounding as Q3 HeyDude and International Sales Improve
Crocs gave investors evidence that several parts of its strategy are working at once. Keeping that progress going could spart the stock’s comeback.
-
What the 2026 Midterm Elections Could Mean for Your Portfolio
The U.S. midterm elections could reshape the outlook for businesses that depend on government spending, regulation, and political support.
-
Is Tower Semiconductor’s AI Expansion Starting to Pay Off In Q3?
Tower Semiconductor delivered margin improvement as it scales revenue, now it has to expand its customer base to support long-term financial targets.
-
AbbVie’s Q3 Shows Why It’s a Biopharma Stock Built to Hold
For investors seeking a biopharma stock to own for the next decade, AbbVie remains one of the best choices available.
Got any book recommendations?